Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats

Biomaterials

Volumn 28, Issue 11, 2007, Pages 1978-1988

  Tatard, Valérie M ^a   Sindji, Laurence ^a  

^a Godbee)   (France)

Author keywords

Drug release; Growth factor; Microspheres; Nerve tissue engineering; Progenitor cell; Transplantation

Indexed keywords

BIOMEDICAL ENGINEERING; CONTROLLED DRUG DELIVERY; GRAFTING (CHEMICAL); NEUROLOGY; PATIENT TREATMENT; PHARMACODYNAMICS; TISSUE; TRANSPLANTATION (SURGICAL);

DRUG RELEASE; GROWTH FACTOR; MICROSPHERES; NERVE TISSUE ENGINEERING; PARKINSON'S DISEASE; PHARMACOLOGICALLY ACTIVE MICROCARRIERS (PAM); PROGENITOR CELLS;

CELLS;

AMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LYSOZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSPLANTATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BIOCOMPATIBLE MATERIALS; BRAIN; CELL DIFFERENTIATION; CELL SURVIVAL; DOPAMINE; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MICROSPHERES; NEURONS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELLS; TISSUE ENGINEERING;

ANIMALIA; RATTUS;

EID: 33846577913     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2006.12.021     Document Type: Article

References (45)

1. Bjorklund A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr Opin Neurobiol 2 5 (1992) 683-689
2. Mendez I., Elisevich K., Naus C., and Flumerfelt B. Restoration of nigrostriatal synaptic circuitry, striatal mRNA expression, and motor symmetry following embryonic substantia nigra grafts. Clin Neurosurg 38 (1992) 180-209
3. Nikkhah G., Cunningham M.G., Cenci M.A., McKay R.D., and Bjorklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci 15 5 Part 1 (1995) 3548-3561
4. Drucker-Colin R., and Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status. Cell Mol Neurobiol 24 3 (2004) 301-315
5. Lindvall O., and Hagell P. Role of cell therapy in Parkinson disease. Neurosurg Focus 13 5 (2002) e2
6. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sanberg P.R., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332 17 (1995) 1118-1124
7. Schierle G.S., Hansson O., Leist M., Nicotera P., Widner H., and Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 5 1 (1999) 97-100
8. Saporta S., Borlongan C., Moore J., Mejia-Millan E., Jones S.L., Bonness P., et al. Microcarrier enhanced survival of human and rat fetal ventral mesencephalon cells implanted in the rat striatum. Cell Transplant 6 6 (1997) 579-584
9. Borlongan C.V., Saporta S., and Sanberg P.R. Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats. Exp Neurol 151 2 (1998) 203-214
10. Cherksey B.D., Sapirstein V.S., and Geraci A.L. Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain. Neuroscience 75 2 (1996) 657-664
11. Bakay R.A., Raiser C.D., Stover N.P., Subramanian T., Cornfeldt M.L., Schweikert A.W., et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci 9 (2004) 592-602
12. Tatard V.M., Venier-Julienne M.C., Benoit J.P., Menei P., and Montero-Menei C.N. In vivo evaluation of pharmacologically active microcarriers releasing nerve growth factor and conveying PC12 cells. Cell Transplant 13 5 (2004) 573-583
13. Tatard V.M., Venier-Julienne M.C., Saulnier P., Prechter E., Benoit J.P., Menei P., et al. Pharmacologically active microcarriers: a tool for cell therapy. Biomaterials 26 17 (2005) 3727-3737
14. Chaturvedi R.K., Agrawal A.K., Seth K., Shukla S., Chauhan S., Shukla Y., et al. Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical and immunohistochemical studies. Int J Dev Neurosci 21 7 (2003) 391-400
15. Rosenblad C., Martinez-Serrano A., and Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75 4 (1996) 979-985
16. Yurek D.M., and Fletcher-Turner A. GDNF partially protects grafted fetal dopaminergic neurons against 6-hydroxydopamine neurotoxicity. Brain Res 845 1 (1999) 21-27
17. Cunningham L.A., and Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 174 2 (2002) 230-242
18. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., et al. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 149 1 (1998) 230-236
19. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154 2 (1998) 261-275
20. Lapchak P.A., Araujo D.M., Hilt D.C., Sheng J., and Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 777 1-2 (1997) 153-160
21. Mandel R.J., Spratt S.K., Snyder R.O., and Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94 25 (1997) 14083-14088
22. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 5 (2003) 589-595
23. Aubert-Pouessel A., Venier-Julienne M.C., Clavreul A., Sergent M., Jollivet C., Montero-Menei C.N., et al. In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Release 95 3 (2004) 463-475
24. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Montero-Menei C.N., Benoit J.P., et al. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci Lett 356 3 (2004) 207-210
25. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Remy S., Montero-Menei C.N., et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 25 5 (2004) 933-942
26. Clavreul A., Sindji L., Aubert-Pouessel A., Benoit J.P., Menei P., and Montero-Menei C.N. Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. Eur J Pharm Biopharm 63 2 (2006) 221-228
27. Aubert-Pouessel A., Bibby D.C., Venier-Julienne M.C., Hindre F., and Benoit J.P. A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres. Pharm Res 19 7 (2002) 1046-1051
28. Margis R., and Borojevic R. Quantification of attached cells in tissue culture plates and on microcarriers. Anal Biochem 181 2 (1989) 209-211
29. Paxinos G., and Watson C. The rat brain in stereotaxic coordonates. 4th ed (1998), Academic Press, New York
30. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 1 (1968) 107-110
31. Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard-Barthelaix A., and Benoit J.P. Biodegradation and brain tissue reaction to poly(d,l-lactide-co-glycolide) microspheres. Biomaterials 14 6 (1993) 470-478
32. Borlongan C.V., Saporta S., and Sanberg P.R. Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats. Exp Neurol 151 2 (1998) 203-214
33. Kim H.K., and Park T.G. Comparative study on sustained release of human growth hormone from semi-crystalline poly(l-lactic acid) and amorphous poly(d,l-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J Control Release 98 1 (2004) 115-125
34. Hudson J., Granholm A.C., Gerhardt G.A., Henry M.A., Hoffman A., Biddle P., et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36 5 (1995) 425-432
35. Sinclair S.R., Svendsen C.N., Torres E.M., Martin D., Fawcett J.W., and Dunnett S.B. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 7 15-17 (1996) 2547-2552
36. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 153 2 (1998) 195-202
37. Menei P., Boisdron-Celle M., Croue A., Guy G., and Benoit J.P. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 39 1 (1996) 117-123 [discussion 123-4]
38. Saporta S., Borlongan C., Moore J., Mejia-Millan E., Jones S.L., Bonness P., et al. Microcarrier enhanced survival of human and rat fetal ventral mesencephalon cells implanted in the rat striatum. Cell Transplant 6 6 (1997) 579-584
39. Subramanian T., Marchionini D., Potter E.M., and Cornfeldt M.L. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant 11 3 (2002) 207-214
40. Brundin P., Barbin G., Isacson O., Mallat M., Chamak B., Prochiantz A., et al. Survival of intracerebrally grafted rat dopamine neurons previously cultured in vitro. Neurosci Lett 61 1-2 (1985) 79-84
41. Rioux L., Gaudin D.P., Bui L.K., Gregoire L., DiPaolo T., and Bedard P.J. Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 40 1 (1991) 123-131
42. Yurek D.M., and Fletcher-Turner A. Temporal changes in the neurotrophic environment of the denervated striatum as determined by the survival and outgrowth of grafted fetal dopamine neurons. Brain Res 931 2 (2002) 126-134
43. Ostenfeld T., Tai Y.T., Martin P., Deglon N., Aebischer P., and Svendsen C.N. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 69 6 (2002) 955-965
44. Rosenblad C. Growth factor treatment of neurodegenerative disorders: new developments pave the way for clinical success. IDrugs 7 3 (2004) 243-248
45. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25 4 (2005) 769-777